الصفحة الرئيسية>>Signaling Pathways>> Cell Cycle/Checkpoint>> PERK>>PERK-IN-5

PERK-IN-5

رقم الكتالوجGC64866

PERK-IN-5 هو مثبط PERK قوي للغاية وانتقائي ومتوفر بيولوجيًا عن طريق الفم (IC50s من 2 و 9 نانومتر لـ PERK و p-eIF2α ، على التوالي)يمكن أن يمنع PERK-IN-5 نمو الورم بشكل كبير في نموذج ورم سرطان الخلايا الكلوية 786-O

Products are for research use only. Not for human use. We do not sell to patients.

PERK-IN-5 التركيب الكيميائي

Cas No.: 2616821-91-9

الحجم السعر المخزون الكميّة
5 mg
675٫00
متوفر
10 mg
1080٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

PERK-IN-5 is a highly potent, selectively and orally bioavailable PERK inhibitor (IC50s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model[1].

PERK-IN-5 (compound 28) (10-48 µM) is relatively stable in both human and dog hepatocytes and is characterized with long half-lives[1].

PERK-IN-5 (3-100 mg/kg; p.o.; 0.25-24 hours) has robust pharmacokinetics in CD1 mice, with Cmax of 3353 ng/mL, AUC0-last of 5153 h*ng/mL, and bioavailability of 70%[1].PERK-IN-5 (3 or 10 mg/kg; p.o.; twice daily, for 28 days) has statistically significant tumor growth inhibition[1].

[1]. Calvo V, et al. Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors. Bioorg Med Chem Lett. 2021;43:128058.

مراجعات

Review for PERK-IN-5

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PERK-IN-5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.